1J. Douchamps,F. Derenne,A. Stockis,D. Gangji,M. Juvent,A. Herchuelz. The pharmacokinetics of oxybutynin in man[J] 1988,European Journal of Clinical Pharmacology(5):515～520
5Temml C, Haidinger G, Schmidbauer J, et al. Urinary incontinence in both sexes:prevalence rates and impact on quality of life and sexual life [ J ]. Neurourol Urodyn,2000,19 (3) :259 - 271.
6Yarker YE, Goa KL, Fitton A, et al. A review of its pharmacodynamic And pharmaco - kinetic properties, and its therapeutic use in detrusor instability [ J ]. Drugs Aging, 1995,6 ( 3 ) :243 - 262.
7Salvatore S, Serati M, Cardozo L, et al. Cognitive dysfunction with tolterodineuse [ J ]. Am J Obstet Gynecol, 2007,197 ( 2 ) :8.
8T Bannowsky A, Wefer B, Braun PM,et al. Urodynamic changes and response rates in patients treated with permanent electrodes compared to conventional wire electrodes in the peripheral nerve evaluation test [ J ]. World J Urol, 2008,26 ( 6 ) :623 - 626.
9Eeva Lukkari, Kari Aranko, Auni Juhakoski, et al. Effect of Time Interval between Food and Drug Ingestion on the Absorption of Oxybutynin from a Controlled-release Tablet[J]. Pharmacology & Toxlcology .1997,81:31
10Appell RA, Sand P, Dmochowski R et al: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study[J]. Mayo Clin Proc 2001,76:358
